{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:09:18Z","timestamp":1790906958749,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Oblimersen sodium plus rituximab was evaluated in relapsed\/refractory B\u2010cell non\u2010Hodgkin lymphoma (NHL) patients. Oblimersen was administered as a continuous intravenous infusion at a daily dose of 3\u2003mg\/kg\/d for 7\u2003d on alternate weeks for 3\u2003weeks. Rituximab was given at a weekly dose of 375\u2003mg\/m<jats:sup>2<\/jats:sup> for six doses. Patients with stable disease or objective response were allowed to receive a second course of treatment. The overall response rate (ORR) was 42% with 10 complete responses (CR) and eight partial responses (PR). Twelve (28%) patients achieved a minimal response or stable disease. Among the 20 patients with follicular lymphoma the ORR was 60% (eight CR, four PR). Three of the responders were refractory to prior treatment with rituximab, and two of the responses occurred in patients who had failed an autologous stem cell transplant. Median duration of response was 12\u2003months. Most toxicities were low grade and reversible. In conclusion, oblimersen sodium can be safely combined with rituximab. The combination appears to be most beneficial in patients with indolent NHL and warrants further investigation in a large randomized trial.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07353.x","type":"journal-article","created":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T16:27:21Z","timestamp":1220286441000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Phase II multicenter study of oblimersen sodium, a Bcl\u20102 antisense oligonucleotide, in combination with rituximab in patients with recurrent B\u2010cell non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"143","author":[{"given":"Barbara","family":"Pro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zwiebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,14]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"808a","article-title":"Bcl\u20102 antisense (Genasense) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells","volume":"98","author":"Auer R.L.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_4_1","first-page":"227a","article-title":"Oblimersen sodium (G3139) sensitizes malignant B\u2010cells to alemtuzumab induced apoptosis","volume":"22","author":"Cotter F.E.","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V90.1.244","article-title":"Prognostic significance of Bcl\u20102 protein expression and Bcl\u20102 gene rearrangement in diffuse aggressive non\u2010Hodgkin\u2019s lymphoma","volume":"90","author":"Gascoyne R.D.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.1.265.265"},{"key":"e_1_2_6_8_1","first-page":"2492","article-title":"Eradication of human non\u2010Hodgkin\u2019s lymphoma in SCID mice by BCL\u20102 antisense oligonucleotides combined with low\u2010dose cyclophosphamide","volume":"6","author":"Klasa R.J.","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_9_1","first-page":"566","article-title":"Phase II study of oblimersen sodium (G3139) alone and with R\u2010CHOP in mantle cell lymphoma (MCL)","volume":"22","author":"Leonard J.P.","year":"2003","journal-title":"Proceedings of American Society of Clinical Oncology"},{"key":"e_1_2_6_10_1","first-page":"143a","article-title":"Genasense (oblimersen sodium, G3139) is active and well tolerated both alone and with R\u2010CHOP in mantle cell lymphoma (MCL)","volume":"102","author":"Leonard J.P.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4364"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.1191"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2941"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.1693.3.12","article-title":"Enhanced efficacy of therapy with antisense BCL\u20102 oligonucleotides plus anti\u2010CD20 monoclonal antibody in scid mouse\/human lymphoma xenografts","volume":"3","author":"Smith M.R.","year":"2004","journal-title":"Molecular Cancer Therapeutics"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1812"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07353.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07353.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:55:00Z","timestamp":1697453700000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07353.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,14]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07353.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07353.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,14]]},"assertion":[{"value":"2008-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}